Abstract: A process for fluid phase in-line blending of plasticized polymers is provided.

Abstract: Provided are bulk homogeneous polymerization processes for producing ethylene propylene random copolymers. The process includes contacting in a reactor or in a series of reactors propylene monomer, ethylene comonomer with one or more catalyst systems and optional solvent (present at less than 40 wt %), wherein the reactor train is at a temperature of between 65° C. and 180° C.

Abstract: Provided are methods and computer program products for monitoring and reporting network application performance in a networked device. Methods may include collecting performance data corresponding to at least one application running on the networked device in substantially real time using at least one kernel space driver interface; generating multiple kernel level metrics and multiple user level metrics based on the collected performance data; aggregating the kernel level metrics and the user level metrics that were generated during a predefined time interval; and generating, responsive to aggregating the kernel level metrics and the user level metrics, an event incorporating the aggregated metrics.

Abstract: A program feature set is compared to a processor feature set. The comparison may be performed in response to restoring the program onto a system or requesting its execution. The processor feature set represents zero, one or more optional hardware features supported by the processor, whereas the program feature set represents zero, one or more optional hardware features the program relies upon in its generated code. Comparison of the feature sets determines whether a particular program may run on a particular processor. Programs may be automatically or manually rebuilt to achieve full compatibility. If the comparison indicates that the program requires a feature not supported by the processor, the program is rebuilt based on the processor feature set. Alternatively, the program may be rebuilt in response to a rebuild request, rather than the comparison. The program is preferably rebuilt from an intermediate representation (IR) stored with or locatable from the program.

Abstract: The present invention provides methods of increasing an amount of a treatment agent in the body, a cancer or tumor. The methods include administering an inhibitor of the metabolic degradation or conversion of the treatment agent to a subject undergoing treatment for a hyperproliferative disorder with said treatment agent. Methods of treating hyperproliferative disorders, tumors and cancers are also provided.

Abstract: The present invention provides an edible composition for oral delivery of an active agent such as a retinide. The composition comprises, in the form of a dry flowable powder: (a) an active agent such as a retinide; (b) lipid matrix composition; (c) optionally sweetener; (d) flour. Compositions of the invention may be administered per se or mixed with a solid or liquid food carrier, for direct oral consumption by a subject or administration through a feeding tube.

Abstract: The present invention provides an edible composition for oral delivery of an active agent such as paclitaxel or a retinide. The composition comprises, in the form of a dry flowable powder: (a) an active agent such as a retinide; (b) lipid matrix composition; (c) optionally sweetener; (d) flour. Compositions of the invention may be administered per se or mixed with a solid or liquid food carrier, for direct oral consumption by a subject or administration through a feeding tube.

Abstract: Provided are processes for feeding ethylene into a polymerization system operating in a liquid phase or supercritical phase.

Abstract: A method of treating a hyperproliferative disorder, including a cancer, in a subject in need of such treatment, comprising administering to said subject a pharmaceutical combination containing a treatment effective amount of: (a) a vitamin A derivative (i.e., a retinoid), or a pharmaceutically acceptable salt thereof, and an inhibitor of microtubule structure or function; or (b) a combination containing fenretinide (i.e., N-(4-hydrophenyl) retinamide, 4-HPR) and ABT-751 (i.e., N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide). Vitamin A derivatives that may be useful for this invention according to (a) include, but are not limited to, all-trans-retinoic acid, 13-cis-retinoic acid, and fenretinide. Microtubule inhibitors that may be useful for this invention according to (a) include, but are not limited to, inhibitors of the Vinca binding domain (e.g., vincristine, vinblastine, vinorelbine, and cryptophycin 52), inhibitors of the Taxane domain (e.g.

Abstract: Provided are methods of producing polymers with broadened molecular weight and/or composition distribution in a continuous homogeneous polymerization system utilizing reactor temperature gradients, reactor polymer concentration gradients, monomer concentration gradients, catalyst concentration gradients, and combinations thereof in the polymerization reactor. Such methods are particularly suitable when utilizing metallocene catalysts and other single-site catalysts, which generally produce polymers with narrow molecular weight and composition distribution.

Abstract: Provided are bulk homogeneous polymerization processes for producing ethylene propylene random copolymers. The process includes contacting in a reactor or in a series of reactors propylene monomer, ethylene comonomer with one or more catalyst systems and optional solvent (present at less than 40 wt %), wherein the reactor train is at a temperature of between 65° C. and 180° C.

Abstract: A process for fluid phase in-line blending of plasticized polymers is provided.

Abstract: The present invention provides stable aqueous solutions consisting essentially of: (a) a sphingolipid; (b) lactic acid; and (c) optionally a stabilizing agent; wherein the solution has a molar ratio of lactic acid to sphingolipid of 1:1 to 10:1. The present invention further provides an emulsion formulation consisting essentially of: (a) lactic acid; (b) a sphingolipid, wherein the sphingolipid is present in an amount of about 0.1 to about 30 mg/ml of emulsion; (b) optionally an isotonic agent; and (c) a phospholipid present in an amount of about 0.2 to about 200 mg/ml of emulsion. Methods of making and using the compositions are also provided.

Abstract: The present invention is generally directed to a method, system, and article of manufacture that ensures the integrity of programs having variable portions. One aspect of this invention is a method for protecting software products having variant portions. This method includes identifying a reference to an external target in a software product, creating an identifier for the external target, and adding the identifier to the reference. In some embodiments, the unique identifier is a digital signature and the reference to an external target is a call to an external library.

Abstract: A process for fluid phase in-line blending of polymers.

Abstract: The present invention is generally directed to a method, system, and article of manufacture that ensures the integrity of programs having variable portions. One aspect of this invention is a method for protecting software products having variant portions. This method includes identifying a reference to an external target in a software product, creating an identifier for the external target, and adding the identifier to the reference. In some embodiments, the unique identifier is a digital signature and the reference to an external target is a call to an external library.

Abstract: A pharmaceutical composition for parenteral delivery, comprising a retinide such as fenretinide in combination with a solvent capable of dispersing or solubilizing the retinide. The solvent comprises an alcohol, such as ethanol, in combination with an alkoxylated castor oil, such as CREMOPHOR® EL, or comprising a retinide, such as fenretinide, in an emulsion composed of a lipoid dispersed in an aqueous phase, a stabilizing amount of a non-ionic surfactant, optionally a solvent, and optionally an isotonic agent. In addition, a method of use in the treatment of hyperproliferative disorders, such as cancers is described.

Abstract: According to one embodiment, a method comprises evaluating messages between nodes of a distributed computing environment. Based on timing relationships of the messages, probability of causal links between pairs of messages determined. Based on the determined probability, at least one causal path comprising a plurality of causal links is inferred. Further, an overall probability that the inferred causal path is accurate is determined. In certain embodiments, the overall probability is output for the corresponding causal path to provide an indication of the confidence of the accuracy of such inferred causal path.

Abstract: The present invention provides an edible composition for oral delivery of an active agent such as paclitaxel or a retinide. The composition comprises, in the form of a dry flowable powder: (a) an active agent such as a retinide; (b) lipid matrix composition; (c) optionally sweetener; (d) flour. Compositions of the invention may be administered per se or mixed with a solid or liquid food carrier, for direct oral consumption by a subject or administration through a feeding tube.

Abstract: A system and method for reporting a user's behavior and patterns when engaged in use of an electronic consumable. In a preferred embodiment, an electronic consumable such as an electronic book or library includes detectors for collecting biological information from a user. This information is analyzed to identify the user's interests in and reactions to the electronic consumable.